Authors
Morgan E Roberts, Natalie M Bath
Published in
Journal of gastrointestinal cancer. Volume 57. Issue 1. Nov 14, 2026. Epub Nov 14, 2026.
Abstract
Histotripsy is an emerging noninvasive, nonthermal ablative therapy recently introduced for the treatment of hepatic malignancies. This systematic review evaluated the efficacy and safety of histotripsy for primary and secondary liver tumors.
PubMed and Scopus were searched from inception through August 2026 in accordance with PRISMA guidelines. Search terms included combinations of subject headings and keywords such as "histotripsy," "hepatic," and "metastases."
Ten clinical studies published between 2022 and 2026 met inclusion criteria. Study populations included hepatocellular carcinoma and metastases from colorectal, neuroendocrine, pancreatic, breast, and other malignancies. Technical success ranged from 68.8% to 100%, although definitions varied across studies. Early treatment efficacy and local control were generally high among successfully treated tumors, with several studies reporting rates exceeding 90%. Longer-term oncologic data were limited by heterogeneous imaging criteria, treatment intent, and patient populations. Major complications were uncommon, although vascular thrombosis and acute kidney injury emerged as potential safety concerns.
Current evidence supports the technical feasibility and short-term efficacy of hepatic histotripsy. However, standardized outcome definitions, longer follow-up, and comparative studies are needed to establish its durability and role relative to existing liver-directed therapies.
PMID:
43033338
Bibliographic data and abstract were imported from PubMed on 15 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0